| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
8.08(B) |
| Last
Volume: |
2,144,916 |
Avg
Vol: |
1,949,015 |
| 52
Week Range: |
$44.82 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
6,762 |
108,398 |
166,494 |
290,334 |
| Total Sell Value |
$463,948 |
$6,570,910 |
$11,277,891 |
$18,676,003 |
| Total People Sold |
8 |
10 |
11 |
11 |
| Total Sell Transactions |
11 |
52 |
61 |
100 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sterling Lionel |
Director |
– • – |
2016-09-01 |
4 |
B |
$18.10 |
$90,500 |
D/D |
5,000 |
121,247 |
2.39 |
- |
|
| Napier Katherine S |
Director |
– • – |
2016-08-03 |
4 |
B |
$17.93 |
$60,613 |
D/D |
3,380 |
105,927 |
2.39 |
- |
|
| Fallon John A. |
Director |
– • – |
2016-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
31,246 |
31,246 |
|
- |
|
| Wyzga Michael S |
Director |
– • – |
2016-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
11,547 |
17,585 |
|
- |
|
| Doyle James Edward |
Director |
– • – |
2016-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
11,547 |
33,006 |
|
- |
|
| Napier Katherine S |
Director |
– • – |
2016-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
11,547 |
102,547 |
|
- |
|
| Thompson David |
Director |
– • – |
2016-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
16,166 |
126,379 |
|
- |
|
| Sterling Lionel |
Director |
– • – |
2016-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
13,856 |
116,247 |
|
- |
|
| Levangie Daniel J |
Director |
– • – |
2016-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
15,156 |
66,478 |
|
- |
|
| Carey Thomas D. |
Director |
– • – |
2016-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
14,867 |
51,635 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2016-07-26 |
4 |
AS |
$14.82 |
$109,416 |
D/D |
(7,383) |
245,209 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2016-07-26 |
4 |
AS |
$14.82 |
$109,060 |
D/D |
(7,359) |
531,377 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2016-07-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
252,592 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2016-07-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
538,736 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2016-07-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
740,057 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2016-07-01 |
4 |
AS |
$12.28 |
$20,188 |
D/D |
(1,644) |
24,697 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2016-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,687 |
26,341 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2016-06-24 |
4 |
OE |
$0.83 |
$128,291 |
D/D |
154,568 |
513,736 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2016-06-22 |
4 |
OE |
$0.83 |
$74,700 |
D/D |
90,000 |
359,168 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2016-05-11 |
4 |
GD |
$0.00 |
$0 |
I/I |
41,994 |
13,706 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2016-05-02 |
4 |
A |
$5.95 |
$14,655 |
D/D |
2,463 |
227,592 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2016-05-02 |
4 |
A |
$5.95 |
$16,363 |
D/D |
2,750 |
715,057 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2016-05-02 |
4 |
A |
$5.95 |
$13,834 |
D/D |
2,325 |
21,654 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2016-04-01 |
4 |
AS |
$6.62 |
$11,155 |
D/D |
(1,685) |
19,329 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2016-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,688 |
21,014 |
|
- |
|
777 Records found
|
|
Page 26 of 32 |
|
|
0.20 (0.44%) 
